EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mean platelet volume and platelet distribution width in combination with prostate-specific antigen to differentiate between prostatic carcinoma and benign prostatic hyperplasia

Soumya M. Hadimani, M. D. Shilpa, Shivaramakrishna Bodapati

Journal of Diagnostic and Academic Pathology · 2026

DOI: 10.4103/jdap.jdap_1_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diagnostic and Academic Pathology, 2026. Verfasst von Soumya M. Hadimani und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In men, the prostatic carcinoma (Pca) is the second most prevalent cancer, and according to Globicon 2022, it is the 5 th predominant cause of cancer death. The prostate-specific antigen (PSA) lacks high specificity and sensitivity rate, which is typically involving over diagnosis, unnecessary biopsy and lacks tumour specificity.Hence, other novel biomarkers which are having high specificity and sensitivity rate along with can be available at patient convenience and affordable prices.

Aims

(1) To determine the association of mean platelet volume (MPV) and platelet distribution width (PDW) in prostate carcinoma and benign prostate hyperplasia and (2) To evaluate the association of clinicopathological parameters of Pca with MPV, PDW and PSA. Materials and Methods: This study included 110 PCa patients and 129 benign prostatic hyperplasia (BPH) patients, which included all clinical and laboratory details of the patient, and the obtained data were analysed for the ability of MPV and PDW alone or in combination with PSA to differentiate between BPH and PCa. To evaluate this area under the ROC curve (AUC) obtained by receiver operating curve was used.

Results

Compared to BPH patients, PCa patients had higher PSA and PDW levels and lower MPV. AUC values for individual biomarkers ranged from 0.941 for PSA to 0.954 for PDW. The AUC was considerably higher when PSA, MPV and PDW were combined than when they were used alone, rising to 0.965 (0.891–0.970).

Conclusions

The combined assessment of PSA with platelet indices such as MPV and PDW offers a novel, inexpensive and easily implementable strategy distinguish BPH from Pca. This triad helps in guiding timely interventions and optimising the patient outcomes.

Zitieren

APA

Hadimani, S. M., Shilpa, M. D., & Bodapati, S. (2026). Mean platelet volume and platelet distribution width in combination with prostate-specific antigen to differentiate between prostatic carcinoma and benign prostatic hyperplasia. Journal of Diagnostic and Academic Pathology. https://doi.org/10.4103/jdap.jdap_1_26

Vancouver

Hadimani SM, Shilpa MD, Bodapati S. Mean platelet volume and platelet distribution width in combination with prostate-specific antigen to differentiate between prostatic carcinoma and benign prostatic hyperplasia. Journal of Diagnostic and Academic Pathology. 2026. doi:10.4103/jdap.jdap_1_26

BibTeX
@article{Hadimani2026,
  author = {Hadimani, Soumya M. and Shilpa, M. D. and Bodapati, Shivaramakrishna},
  title = {Mean platelet volume and platelet distribution width in combination with prostate-specific antigen to differentiate between prostatic carcinoma and benign prostatic hyperplasia},
  journal = {Journal of Diagnostic and Academic Pathology},
  year = {2026},
  doi = {10.4103/jdap.jdap_1_26}
}
Kostenlos starten →